TAK733

TAK-733是一种有效的，选择性的MEK变构抑制剂，作用于MEK1，IC50为3.2 nM，抑制Abl1， AKT3， c-RAF， CamK1， CDK2及c-Met等活性。Phase 1。TAK-733 is highly potent and selective MEK allosteric site inhibitor with IC50 of 3.2 nM. TAK-733 shows potent enzymatic and cell activity with an EC50 of 1.9 nM against ERK phosphorylation in cells.TAK-733 demonstrates broad antitumor activity in mouse xenograft models of human cancer including models of melanoma, colorectal, NSCLC, pancreatic and breast cancer. TAK-733 is well tolerated with pharmacokinetics and pharmacodynamics that support once-daily oral dosing in humans. TAK-733 shows maximally efficacious doses at once daily orally doses of 10 mg/kg.TAK-733是一种有效的，选择性的MEK变构抑制剂，作用于MEK1，IC50为3.2 nM，抑制Abl1， AKT3， c-RAF， CamK1， CDK2及c-Met等活性。Phase 1。

Target	Value
MEK1 (Cell-free assay)	3.2 nM

TAK-733是高度有效的选择性MEK变构位点抑制剂，IC50 为3.2 nM。TAK-733表现出有效的酶和细胞活性，对细胞中ERK磷酸化作用的EC50为1.9 nM。

TAK-733在人体肿瘤，包括黑色素瘤，结肠直肠癌，NSCLC，胰腺癌和乳腺癌的小鼠异种移植物模型中表现出广谱抗肿瘤活性。TAK-733具有良好的药代动力学和药效动力学耐受性，对于人类可每天一次口服给药。 TAK-733的最大有效剂量为10 mg/kg，每天一次。